Wall Street Zen upgraded Treace Medical Concepts (NASDAQ:TMCI) from a “sell” to a “hold” rating, though the consensus remains a “Reduce” with an average price target of $4.21. The stock is trading below its 50-day and 200-day moving averages, indicating a continued downtrend despite the company reporting an EPS beat and revenue slightly above estimates. Analysts forecast a negative EPS of -0.92 for the current year.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Treace Medical Concepts (NASDAQ:TMCI) Upgraded at Wall Street Zen
Wall Street Zen upgraded Treace Medical Concepts (NASDAQ:TMCI) from a “sell” to a “hold” rating, though the consensus remains a “Reduce” with an average price target of $4.21. The stock is trading below its 50-day and 200-day moving averages, indicating a continued downtrend despite the company reporting an EPS beat and revenue slightly above estimates. Analysts forecast a negative EPS of -0.92 for the current year.